HEK293 Bioreactor Transfection For Vaccine Applications

Vaccines are valuable tools to minimize the risk of infectious diseases, and many vaccines subtypes exist with the goal to train the immune system to fight certain infectious agents and thus provide protection for future infections. In order to advance vaccine production and to enable sufficient protection against prevalent and future pathogens, scalable vaccine production strategies are needed.

In this application note, a bioreactor-based SARS-CoV-2 S HexaPro spike protein production was developed using a suspension cell culture platform to demonstrate the feasibility of producing large quantities of vaccine components using the suspension-adapted HEK293 cell platform Expi293F™ transfected with spike-protein-encoding plasmid DNA.